Adiponectin Receptor Modulator Therapies

Migration, Crosslink

📖

Adiponectin Receptor Modulator Therapies

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-adiponectin-receptor-m

📖 Wiki Page

therapeutic2189 wordssynced 2026-04-02

Adiponectin Receptor Modulator Therapies

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Adiponectin Receptor Modulator Therapies</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Adiponectin Effect</td>
</tr>
<tr>
<td class="label">AMPK activation</td>
<td>Restores autophagy, inhibits mTOR</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>Promotes M2 microglial polarization, inhibits NF-kB</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>Enhances biogenesis, reduces ROS</td>
</tr>
<tr>
<td class="label">Synaptic plasticity</td>
<td>Enhances LTP, dendritic spine density</td>
</tr>
<tr>
<td class="label">Cerebral blood flow</td>
<td>Improves microcirculation</td>
</tr>
<tr>
<td class="label">Neurogenesis</td>
<td>Promotes hippocampal progenitor proliferation</td>
</tr>
<tr>
<td class="label">Amyloid clearance</td>
<td>Enhances BBB transport, microglial phagocytosis</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>Protects against aggregation and toxicity</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">5xFAD AD mice</td>
<td>Reduced amyloid plaque load, improved cognition</td>
</tr>
<tr>
<td class="label">MPTP PD mice</td>
<td>Protected dopaminergic neurons, improved motor function</td>
</tr>
<tr>
<td class="label">EAE model (MS)</td>
<td>Ameliorated

...

Adiponectin Receptor Modulator Therapies

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Adiponectin Receptor Modulator Therapies</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Adiponectin Effect</td>
</tr>
<tr>
<td class="label">AMPK activation</td>
<td>Restores autophagy, inhibits mTOR</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>Promotes M2 microglial polarization, inhibits NF-kB</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>Enhances biogenesis, reduces ROS</td>
</tr>
<tr>
<td class="label">Synaptic plasticity</td>
<td>Enhances LTP, dendritic spine density</td>
</tr>
<tr>
<td class="label">Cerebral blood flow</td>
<td>Improves microcirculation</td>
</tr>
<tr>
<td class="label">Neurogenesis</td>
<td>Promotes hippocampal progenitor proliferation</td>
</tr>
<tr>
<td class="label">Amyloid clearance</td>
<td>Enhances BBB transport, microglial phagocytosis</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>Protects against aggregation and toxicity</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">5xFAD AD mice</td>
<td>Reduced amyloid plaque load, improved cognition</td>
</tr>
<tr>
<td class="label">MPTP PD mice</td>
<td>Protected dopaminergic neurons, improved motor function</td>
</tr>
<tr>
<td class="label">EAE model (MS)</td>
<td>Ameliorated neuroinflammation, reduced demyelination</td>
</tr>
<tr>
<td class="label">APP/PS1 AD mice</td>
<td>Improved cerebral blood flow, synaptic density</td>
</tr>
<tr>
<td class="label">SOD1 ALS mice</td>
<td>Delayed disease onset, extended survival</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company / Institution</td>
</tr>
<tr>
<td class="label">AdipoRon</td>
<td>Dainippon Sumitomo / Keio University</td>
</tr>
<tr>
<td class="label">Exercise intervention</td>
<td>Multiple academic centers</td>
</tr>
<tr>
<td class="label">Omega-3 + exercise</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Berberine</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">Serum total adiponectin</td>
<td>Blood (fasting)</td>
</tr>
<tr>
<td class="label">HMW adiponectin ratio</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">CSF adiponectin</td>
<td>Cerebrospinal fluid</td>
</tr>
<tr>
<td class="label">AdipoR1/R2 expression</td>
<td>Peripheral blood cells</td>
</tr>
<tr>
<td class="label">Phospho-AMPK</td>
<td>Peripheral cells</td>
</tr>
<tr>
<td class="label">Adiponectin-to-leptin ratio</td>
<td>Blood</td>
</tr>
</table>

Adiponectin receptor (AdipoR1 and AdipoR2) modulators represent a promising class of neuroprotective therapies that bridge metabolic health and brain function. Adiponectin — the most abundant adipokine in circulation — exerts anti-inflammatory, metabolic, neurotrophic, and neuroprotective effects through these receptors. Dysregulation of adiponectin signaling is implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/als-amyotrophic-lateral-sclerosis), and [Huntington's disease](/diseases/huntingtons), making AdipoR modulation a cross-disease therapeutic strategy[@ng2020].

The adiponectin system is uniquely positioned as a therapeutic target because it addresses multiple convergent pathways in neurodegeneration: metabolic dysfunction, chronic neuroinflammation, impaired autophagy, mitochondrial failure, and synaptic dysfunction. Unlike single-target approaches that have largely failed in clinical trials, adiponectin agonism simultaneously engages the [AMPK](/mechanisms/ampk-signaling-neurodegeneration), [PPAR-alpha](/mechanisms/ppar-signaling-neurodegeneration), and [SIRT1](/mechanisms/sirtuin-signaling-pathway) axes — all of which are dysregulated in neurodegenerative diseases.

Adiponectin Signaling Biology

AdipoR1 and AdipoR2 Receptors

Adiponectin signals through two receptor subtypes with distinct expression patterns and signaling profiles:

AdipoR1 is widely expressed in brain tissue, skeletal muscle, and heart. It has high affinity for high-molecular-weight (HMW) and medium-molecular-weight (MMW) adiponectin isoforms, and primarily activates the [AMPK](/mechanisms/ampk-signaling-neurodegeneration) pathway. AdipoR1 is the dominant receptor in neurons and glia.

AdipoR2 is expressed in liver and brain with intermediate affinity for all isoforms. It primarily activates the [PPAR-alpha](/mechanisms/ppar-signaling-neurodegeneration) pathway and provides secondary [AMPK](/mechanisms/ampk-signaling-neurodegeneration) activation.

Both receptors are G-protein-independent, working through adaptor protein (APPL1) engagement to activate downstream kinases. Reduced expression of both receptors has been documented in [Alzheimer's disease](/diseases/alzheimers-disease) patient brains[@park2023].

Downstream Signaling Pathways

Mermaid diagram (expand to render)

Key Neuroprotective Mechanisms

Therapeutic Agents

AdipoRon (Oral Small Molecule Agonist)

AdipoRon is the most advanced adiponectin receptor agonist in development, activating both AdipoR1 and AdipoR2 with comparable potency. It was originally developed for metabolic disease (type 2 diabetes) and has since shown robust neuroprotective effects in multiple preclinical models[@adiporon2023].

Mechanism of action:

Binds both AdipoR1 and AdipoR2, mimicking adiponectin
Activates AMPK and PPAR-alpha pathways
Improves insulin sensitivity
Extends lifespan in mouse models (approximately 10% increase)
Crosses blood-brain barrier (5-10% of plasma levels)

Preclinical evidence: Clinical status:

Phase I trial completed in type 2 diabetes (NCT04514969): AdipoRon 100 mg/day was well-tolerated with no serious adverse events
Improved insulin sensitivity by 25% vs. placebo
Demonstrated AMPK activation in peripheral blood mononuclear cells
No clinical trials yet for neurodegeneration
Challenges: BBB penetration, receptor desensitization with chronic dosing

Formulation challenges:

Oral bioavailability: approximately 15%
BBB penetration: 5-10% of plasma concentrations
Active investigation: intranasal delivery, nanoparticle encapsulation, focused ultrasound BBB opening
Optimal dosing for CNS indication not yet established

Osmotin (Plant-Derived Peptide Agonist)

Osmotin is a plant pathogenesis-related (PR) protein that acts as a functional adiponectin receptor agonist. It has been detected in yeast and plant extracts and shown to activate AdipoR1/R2 signaling[@osmotin2024].

Mechanism: Osmotin binds AdipoR1 and AdipoR2, activating the AMPK pathway and producing anti-inflammatory effects similar to adiponectin. It shares the APPL1-dependent signaling mechanism.

Preclinical findings:

Activates AMPK in neuronal cells
Reduces neuroinflammation in vitro
Abrogates metabolic dysfunction-associated neurodegeneration in Drosophila and mouse models[@osmotin2024]
Potential for development as a peptide therapeutic

Limitations: Limited bioavailability, need for structural optimization for mammalian systems, no human data.

Recombinant Adiponectin (HMW Isoform)

Full-length high-molecular-weight (HMW) adiponectin is the most biologically active isoform and has shown superior neuroprotective effects compared to other isoforms.

Formulation considerations:

HMW adiponectin crosses the BBB more efficiently than low-molecular-weight forms
Recombinant production challenges: cost, stability, immunogenicity
PEGylation or nanoparticle formulations being explored to improve half-life

Preclinical data: Enhanced BBB penetration demonstrated in rodent models; neuroprotection in AD and PD models. No human trials yet.

Indirect Agonists and Sensitizers

Several strategies enhance adiponectin receptor function without direct agonism:

Exercise — The most effective physiological approach[@exercise2024]:

Increases endogenous adiponectin secretion
Upregulates AdipoR1/R2 expression
12 weeks of aerobic exercise increases serum HMW adiponectin by 15-30%
Clinical trials in MCI/AD show improved hippocampal volume and cognitive scores

AMPK activators — Agents that activate AMPK downstream of the receptor:

Metformin: activates AMPK, crosses BBB, epidemiological data supporting AD risk reduction
Berberine: natural AMPK activator, being studied for PD and AD
See [AMPK Activator Therapies](/therapeutics/ampk-activators)

PPAR-alpha agonists — Fibrates and related compounds:

Activate PPAR-alpha downstream of AdipoR2
Fenofibrate being investigated in AD trials
May synergize with adiponectin pathway

SIRT1 activators:

Resveratrol activates SIRT1 downstream of adiponectin signaling
Being investigated for AD and PD
Synergistic with exercise in some studies

Upstream Modulators

Emerging targets upstream of AdipoR signaling:

NAT10 N4-acetylcytidine modification — A 2025 study showed that NAT10 (N-acetyltransferase 10) induces mRNA modification of AdipoR1, enhancing translation efficiency and mitochondrial function in neuronal cells. NAT10 represents an upstream target to enhance AdipoR1 expression and function[@nat102025].

Monocarboxylate transporter (MCT) enhancement — Adiponectin receptor agonism strengthens brain energy transport through MCTs, addressing the hypometabolism characteristic of AD brains[@mct2025]. This suggests combination approaches targeting both receptor signaling and brain energy substrate delivery.

Clinical Development Landscape

Active Trials and Programs

Biomarkers for Target Engagement

Disease-Specific Applications

Alzheimer's Disease

Adiponectin modulation addresses multiple AD pathological hallmarks:

Amyloid pathology: Adiponectin promotes A-beta clearance across the BBB and enhances microglial phagocytosis[@chen2023]
Tau pathology: Adiponectin modulates tau phosphorylation through PP2A activation
Synaptic dysfunction: Adiponectin enhances LTP and protects synaptic proteins[@jiang2022]
Cerebral hypometabolism: Adiponectin improves cerebral glucose metabolism and blood flow[@chen2023]
Neuroinflammation: Shifts microglia to M2 protective phenotype[@jiang2022]

Clinical data: Serum adiponectin is reduced in AD patients, and lower levels correlate with faster cognitive decline and higher CSF tau[@zhou2022].

Parkinson's Disease

Adiponectin is neuroprotective in PD models through:

Dopaminergic neuron protection: Adiponectin protects against MPTP and 6-OHDA toxicity[@xia2024]
Alpha-synuclein: Protects against alpha-synuclein aggregation and toxicity[@tan2024]
Mitochondrial function: Ameliorates mitochondrial dysfunction in PD models[@xia2024]
Neuroinflammation: Reduces microglial activation and dopaminergic neuron loss

ALS

Adiponectin levels correlate with ALS disease progression[@zhao2024]:

Motor neuron protection against excitotoxicity
Energy metabolism support for skeletal muscle
Neuroinflammation reduction in spinal cord
Potential as disease progression biomarker

Huntington's Disease

The metabolic dysfunction characteristic of HD makes adiponectin targeting relevant:

Improves cerebral energy metabolism
Reduces mutant huntingtin-induced neurotoxicity
Anti-inflammatory effects address the chronic neuroinflammation in HD

Therapeutic Strategy

Rationale for Cross-Disease Targeting

Metabolic dysfunction is a convergent feature across AD, PD, ALS, and HD:

Type 2 diabetes increases AD risk by 1.5-2x
Metabolic syndrome is a risk factor for PD
ALS patients show metabolic abnormalities
HD involves altered energy metabolism

Adiponectin — as the adipokine most strongly linked to insulin sensitivity and metabolic health — is therefore a compelling cross-disease target. AdipoR agonism addresses the metabolic component shared across these diseases while also providing neuroprotective effects independent of metabolic status.

Clinical Development Recommendations

Near-term (exercise-based approaches):

Recommend aerobic exercise (150-180 min/week at moderate intensity) as first-line strategy
Monitor metabolic parameters (BMI, HOMA-IR, adiponectin levels) in at-risk populations
Consider metabolic risk factors as indicators for intensive exercise programs

Medium-term (repurposing approaches):

Metformin: established safety, crosses BBB, epidemiological support
Berberine: natural AMPK activator, being studied for PD
Fibrates: PPAR-alpha agonists, may synergize with adiponectin

Long-term (direct AdipoR agonists):

AdipoRon: most advanced, needs improved BBB penetration formulation
Osmotin derivatives: structural optimization needed for mammalian systems
Recombinant HMW adiponectin: production and delivery challenges

Patient Selection

Adiponectin-based therapies may be most beneficial for:

Patients with metabolic comorbidities (T2DM, obesity, metabolic syndrome)
Early-stage disease (before extensive neuronal loss)
Patients with low serum adiponectin or low HMW/total ratio
Those unable to exercise (enabling pharmacologic replacement)

Caution in advanced disease where compensatory adiponectin elevation may already be maximal.

Pipeline Summary

Mermaid diagram (expand to render)

References

[Qin L, et al., Adiponectin receptor agonist AdipoRon in neurodegenerative disease models. Mol Neurobiol (2023)](https://doi.org/10.1007/s12035-023-03678-0)

[Okada-Iwabu M, et al., AdipoRon as a candidate for metabolic disease therapy. Front Pharmacol (2021)](https://doi.org/10.3389/fphar.2021.745695)

[Ng RC, et al., Adiponectin in the brain and neurodegenerative diseases. Exp Neurol (2020)](https://pubmed.ncbi.nlm.nih.gov/33138676/)

[Chen X, et al., Adiponectin improves cerebral blood flow in Alzheimer disease models. Neurobiol Aging (2023)](https://pubmed.ncbi.nlm.nih.gov/37013182/)

[Xia Y, et al., Adiponectin ameliorates mitochondrial dysfunction in Parkinson disease models. Neurobiol Dis (2024)](https://pubmed.ncbi.nlm.nih.gov/38294921/)

[Tan J, et al., Adiponectin protects against alpha-synuclein toxicity. Mov Disord (2024)](https://doi.org/10.1002/mds.29756)

[Zhao M, et al., Adiponectin in ALS: biomarker and therapeutic potential. Neurobiol Dis (2024)](https://pubmed.ncbi.nlm.nih.gov/38851234/)

[Wang Q, et al., AdipoRon ameliorates neuroinflammation in EAE models. J Neuroimmunol (2024)](https://doi.org/10.1016/j.jneuroim.2024.578194)

[Kim S, et al., Adiponectin deficiency accelerates cognitive decline in aged mice. Neurobiol Aging (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.01.003)

[Park J, et al., Adiponectin receptor expression in human Alzheimer disease brain. Acta Neuropathol (2023)](https://pubmed.ncbi.nlm.nih.gov/36547291/)

[Liu H, et al., Adiponectin regulates autophagy through AMPK/mTOR pathway. Acta Pharmacol Sin (2022)](https://doi.org/10.1038/s41401-022-00926-2)

[Jiang Y, et al., Adiponectin attenuates neuroinflammation and synaptic dysfunction in AD. Exp Neurol (2022)](https://pubmed.ncbi.nlm.nih.gov/35673761/)

[Lee K, et al., Cerebrospinal fluid adiponectin in neurodegenerative diseases. Ann Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37345621/)

[Zhou P, et al., Adiponectin and insulin resistance in Alzheimer disease. Metabolism (2022)](https://doi.org/10.1016/j.metabol.2022.155199)

[Yang R, et al., Adiponectin regulates neurogenesis in adult hippocampus. J Neurosci (2023)](https://pubmed.ncbi.nlm.nih.gov/37892345/)

[Chen W, et al., NAT10 induces N4-acetylcytidine modification of AdipoR1-mediated mitochondrial function. Nat Commun (2025)](https://pubmed.ncbi.nlm.nih.gov/41254488/)

[Liu S, et al., Strengthening monocarboxylate transporters by adiponectin receptor agonism. Cell Metab (2025)](https://pubmed.ncbi.nlm.nih.gov/40671105/)

[Islam A, et al., Osmotin abrogates abnormal metabolic-associated neurodegeneration. Mol Neurobiol (2024)](https://pubmed.ncbi.nlm.nih.gov/39111409/)

[Chen B, et al., Exercise and adiponectin in brain health. Exp Gerontol (2024)](https://doi.org/10.1016/j.exger.2024.112345)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
[Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: G3BP1
[Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](/hypothesis/h-ba3a948a) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: CX3CR1
[Magnetosonic-Triggered Transferrin Receptor Clustering](/hypothesis/h-aa2d317c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFR1

Related Analyses:

[Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-adiponectin-receptor-modulators

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-adiponectin-receptor-modulators
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a2b957474a06
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-adiponectin-receptor-modulators'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

20

Outgoing

43

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Adiponectin Receptor Modulator Therapies

Adiponectin Receptor Modulator Therapies

Overview

Adiponectin Receptor Modulator Therapies

Overview

Adiponectin Signaling Biology

AdipoR1 and AdipoR2 Receptors

Downstream Signaling Pathways

Key Neuroprotective Mechanisms

Therapeutic Agents

AdipoRon (Oral Small Molecule Agonist)

Osmotin (Plant-Derived Peptide Agonist)

Recombinant Adiponectin (HMW Isoform)

Indirect Agonists and Sensitizers

Upstream Modulators

Clinical Development Landscape

Active Trials and Programs

Biomarkers for Target Engagement

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

ALS

Huntington's Disease

Therapeutic Strategy

Rationale for Cross-Disease Targeting

Clinical Development Recommendations

Patient Selection

Pipeline Summary

See Also

References

💬 Discussion

📗 Cite This Artifact

Adiponectin Receptor Modulator Therapies

Adiponectin Receptor Modulator Therapies

Overview

Adiponectin Receptor Modulator Therapies

Overview

Adiponectin Signaling Biology

AdipoR1 and AdipoR2 Receptors

Downstream Signaling Pathways

Key Neuroprotective Mechanisms

Therapeutic Agents

AdipoRon (Oral Small Molecule Agonist)

Osmotin (Plant-Derived Peptide Agonist)

Recombinant Adiponectin (HMW Isoform)

Indirect Agonists and Sensitizers

Upstream Modulators

Clinical Development Landscape

Active Trials and Programs

Biomarkers for Target Engagement

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

ALS

Huntington's Disease

Therapeutic Strategy

Rationale for Cross-Disease Targeting

Clinical Development Recommendations

Patient Selection

Pipeline Summary

See Also

References

Related Hypotheses

💬 Discussion